Jan Steffel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

There are scenarios when the agents may be harmful, and others where more evidence is urgently needed.

Adaptive resynchronization therapy can benefit patients with heart failure, intact atrioventricular conduction, and left bundle branch block, even though the AdaptResponse trial technically failed.

The study missed its primary endpoint, but researchers still see good reason to use the dynamic LV-pacing algorithm in HFrEF.

Optimization of drug therapy for HF “doesn’t necessarily obviate the necessity for an ICD,” Jan Steffel says.

April 29, 2021 The European Heart Rhythm Association (EHRA) has come out with the fourth iteration of its practical guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF), which has helped physicians deploy these medications since it first came out in 2013. Senior author Hein Heidbüchel, MD, PhD (Antwerp University Hospital, Belgium), past president of EHRA, explained that the guide is meant to supplement and not supplant clinical practice guidelines. The comprehensive document covers everything from dosing and drug-drug interaction...